全文获取类型
收费全文 | 111篇 |
免费 | 6篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 5篇 |
临床医学 | 6篇 |
内科学 | 11篇 |
神经病学 | 2篇 |
外科学 | 12篇 |
预防医学 | 1篇 |
药学 | 6篇 |
肿瘤学 | 69篇 |
出版年
2021年 | 2篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2014年 | 1篇 |
2012年 | 3篇 |
2010年 | 5篇 |
2009年 | 4篇 |
2008年 | 2篇 |
2007年 | 6篇 |
2006年 | 5篇 |
2005年 | 11篇 |
2004年 | 6篇 |
2003年 | 2篇 |
2002年 | 1篇 |
2001年 | 6篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 1篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 8篇 |
1989年 | 7篇 |
1988年 | 8篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1979年 | 2篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1972年 | 1篇 |
排序方式: 共有117条查询结果,搜索用时 15 毫秒
1.
Current status of the therapy of advanced renal carcinoma. 总被引:1,自引:0,他引:1
A preclinical murine renal model system is available for evaluation of the effectiveness of therapeutic agents. Clinical review reveals that objective response rates to hormonal agents reported since 1971 have been substantially lower than those reported prior to 1971. Many chemotherapeutic agents have not been adequately evaluated clinically or with the experimental model. Vinblastine to date may be the most active single agent with a 25% objective response rate. At the present time, it is uncertain whether combination chemotherapy or hormonal chemotherapy add to response rates obtained with single agents. There is some evidence that immunotherapy may be of some adjuvant benefit and, thus may provide an additional avenue of investigation. 相似文献
2.
Retsky M Demicheli R Hrushesky W Speer J Swartzendruber D Wardwell R 《Breast cancer research : BCR》2005,7(1):37-40
The combination of mathematics--queen of sciences--and the general utility of computers has been used to make important inroads into insight-providing breast cancer research and clinical aids. These developments are in two broad areas. First, they provide useful prognostic guidelines for individual patients based on historic evidence. Second, by suggesting numeric tumor growth laws that are correlated to clinical parameters, they permit development of biologically relevant theories and comparison with patient data to help us understand complex biologic processes. These latter studies have produced many new ideas that are testable in clinical trials. In this review we discuss these developments from a clinical perspective, and ask whether and how they translate into useful tools for patient treatment. 相似文献
3.
4.
W J Hrushesky B Lester D Lannin 《International journal of cancer. Journal international du cancer》1999,83(3):365-373
To understand whether mammalian circadian time structure measurably affects the host-cancer balance, we studied tumor-take frequency after s.c. tumor cell inoculation and the number of pulmonary tumor nodules after i.v. tumor cell injections at each of 6 equispaced times of day. We employed 2 genetically distinct mouse strains and 2 different tumor model systems, a methylcholanthrene A-induced fibrosarcoma of C(3)HeJ mice and 2 B(16) melanoma cell lines of vastly different metastatic efficiency in C57 Black/6 mice. Fibrosarcoma cells were injected s.c. in 1 of 8 different doses, at 1 of 8 permutated anatomic sites and at 1 of 6 equispaced circadian times, in 96 female C(3)HeJ mice maintained under a synchronizing schedule of 12 hr light alternating with 12 hr dark. Regardless of tumor cell dose and inoculum location, tumor-take frequency depended strongly upon the circadian stage of tumor cell inoculation. Injections of between 2,000 and 50,000 live tumor cells inoculated near the daily sleep/wake interface resulted in the lowest incidence of tumor take compared with inoculation at other times of day. In the experimental i.v. B(16) melanoma metastatic model (N = 110), the capacity of both high and low metastatic potential clones to successfully metastasize to lung depended, to a large extent, upon when in the day each of these clones was injected. Similar to the fibrosarcoma data, the daily sleep/wake boundary was the time of day associated with the greatest resistance to metastatic spread. 相似文献
5.
6.
FUDR (5-fluoro-2'-deoxyuridine) is one of the few chemotherapeutic agents with activity against metastatic renal cell cancer. Diarrhea and dehydration with long-term, constant-rate intravenous infusion may be severe and life-threatening. This gastrointestinal toxicity can be reduced by altering the rate of the infusion so that most of the daily dose is given late in the day, and a minimal infusion rate is delivered in the early morning hours. This complex therapy can be automatically administered by the programmable, implantable Synchro-Med Infusion System. Using a circadian modification of infusion delivery, toxicity is diminished and the FUDR dose can be safely increased, which may result in greater anti-tumor activity. This paper describes Phase I studies with 54 patients who were treated with intravenous FUDR. It also discusses results of a Phase II study using circadian-modified intravenous delivery of FUDR in the treatment of 61 patients with renal cell cancer. It outlines the nursing implications for management of the implantable, programmable drug delivery system and addresses the nursing role in preventing, recognizing, and controlling FUDR-associated toxicities. 相似文献
7.
8.
Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma 总被引:2,自引:0,他引:2
W J Hrushesky R von Roemeling R M Lanning J T Rabatin 《Journal of clinical oncology》1990,8(9):1504-1513
Sixty-eight unselected patients with progressive metastatic renal cell carcinoma (RCC) were treated between March 1985 and November 1988 with continuous infusion floxuridine (FUDR). Thirty-seven percent of these patients had previously received and failed systemic treatment. Using implantable pumps for automatic drug delivery, FUDR was continuously infused for 14 days at monthly intervals. The starting dose was 0.15 mg/kg/d (intravenous [IV]; n = 61) or 0.25 mg/kg/d (intraarterial [IA]; n = 7); IV doses were increased or decreased in increments of 0.025 mg/kg/d as permitted by toxicity. Diarrhea (with or without mild abdominal cramping) and nausea/vomiting limited the FUDR IV infusion, and hepatic function abnormalities limited FUDR IA infusion. The use of a circadian-modified infusion schedule permitted high FUDR doses to be safely given as compared with a constant rate infusion schedule. Of 63 patients assessable for response, 56 received systemic FUDR infusion. Four complete responses (CRs; 7.1%); and seven partial responses (PRs; 12.5%) were observed (objective response rate, CR plus PR, 19.6 +/- 5.1% [95% confidence limits] ). The median objective response duration was 10.8 months (range, 1 to 18 months; mean, 9.4 +/- 1.6). Four additional patients had minor tumor responses (MRs; 7.1%). In a subgroup of seven assessable patients receiving hepatic arterial FUDR, we observed one CR and three PRs (57.2 +/- 42.8%). Overall, objective response (CR plus PR) was seen in a quarter of assessable patients treated, 15 of 63, while only 15 of the 63 assessable patients (25.4%) have had objective tumor progression. The median follow-up time for all 68 patients was 28 months (range, 1 to 42), and their median survival duration is 15 months (range, 3 to 37 months). Continuous infusion FUDR is an effective outpatient treatment for progressive metastatic RCC, producing durable tumor response and causing little toxicity. 相似文献
9.
S A Gruber G R Erdmann B A Burke A Moss L Bowers W J Hrushesky R J Cipolle D M Canafax A J Matas 《Transplantation》1992,53(1):12-19
We utilized a canine renal transplant model to estimate the first-pass extraction of mizoribine (MZB) during renal artery infusion and to compare the efficacy and toxicity of continuous intraarterial (i.a.) versus intravenous (i.v.) MZB delivery, with and without a background of oral cyclosporine. Five autotransplanted mongrel dogs with programmable, implantable pump/catheter systems were given MZB by both i.v. bolus (5 mg/kg) and i.a. infusion (5.0 mg/kg/day). Mean +/- SD elimination half-life was 3.02 +/- 0.81 hr, and the transplanted kidney removed as much as 47-59% (mean 56%) of locally infused MZB. With increasing local and systemic MZB delivery in a single autografted dog undergoing both i.a. and i.v. pump/catheter placement, renal extraction decreased from at least 47% (5.0 mg/kg/day) to 33% (7.5 mg/kg/day), finally to 18% (10.0 mg/kg/day). A dose of 3.0 mg/kg/day MZB did not significantly prolong survival of renal allograft recipients over that of untreated controls (median survival time [MST] = 8 days) when administered either locally (MST = 9 days) or systemically (MST = 12 days). All dogs receiving 4.0 mg/kg/day MZB i.a. died from rejection, and a survival advantage was still not realized (MST = 7 days). In contrast, 4.0 mg/kg/day i.v. prolonged survival over controls (MST = 14 days; P = 0.03) but not when directly compared with the i.a. group (P = 0.30), and produced death from severe debility in five of seven animals with significantly higher mean systemic MZB levels (P = 0.02). Four of six dogs receiving 5.0 mg/kg/day MZB i.a. (MST = 14 days) and two of four dogs receiving 5.0 mg/kg/day i.v. (MST = 14 days) died from severe debility, though survival in both groups was prolonged over control values (P = 0.01 and P = 0.05, respectively). Coadministration of a subtherapeutic dose of oral CsA (5 mg/kg/day) significantly prolonged the overall survival of dogs receiving MZB 4.0 mg/kg/day i.a. (MST = 23; P = 0.01) but not i.v. (MST = 11; P = 1.00), so that a significant difference in overall survival between the combined MZB i.a. + CSA and MZB i.v. + CSA groups was now realized in favor of the former (P = 0.04). We conclude that at local doses required to achieve immunosuppression, the transplanted kidney was not able to extract enough MZB to prevent death from systemic toxicity, presumably as a result of saturation of renal elimination mechanisms, so that an overall survival benefit was not realized.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
10.
Charles L. Bennett Sumimasa Nagai Andrew C. Bennett Shamia Hoque Chadi Nabhan Martin W. Schoen William J. Hrushesky Stefano Luminari Paul Ray Paul R. Yarnold Bart Witherspoon Josh Riente Laura Bobolts John Brusk Rebecca Tombleson Kevin Knopf Marc Fishman Y. Tony Yang Kenneth R. Carson Benjamin Djulbegovic John Restaino James O. Armitage Oliver A. Sartor 《The oncologist》2021,26(8):e1418-e1426